Results 51 to 60 of about 27,707 (119)

Effect of GLP-1 receptor agonist on nutrient intake: A narrative review. [PDF]

Nutr Clin Pract
Fujioka K.
europepmc   +1 more source

Patient-Reported Continuity of GLP-1 Receptor Agonist Therapy. [PDF]

Obes Sci Pract
Chen Y, Piantek G, Zhang X, Feng Y, Yan C, Samuels JM, Rosenbloom ST, Yu D, Novak LL, Srivastava G.   +9 more
europepmc   +1 more source

Reappraising obesity management in the GLP-1 receptor agonist era. [PDF]

NPJ Metab Health Dis
Christmas T, Ahmed AR, Tan TM.
europepmc   +1 more source

Periconceptional GLP-1 Receptor Agonist Exposure: Lower Observed Risk or Lower Certainty? [PDF]

JACC Adv
Singh R, Singh A, Singh AK.
europepmc   +1 more source

GLP-1 Receptor Agonist Use in Cancer Survivors-Challenges and Opportunities: A Narrative Review. [PDF]

Cancers (Basel)
Agurs-Collins T, Sauter ER.
europepmc   +1 more source

Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist. [PDF]

Front Pharmacol
Ramadurgum P, Shah J, Shah E, Palmer BF.
europepmc   +1 more source

Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study. [PDF]

Medicine (Baltimore)
Khan SA, Subedi A, Marasini A, Shrestha A, Jha S, Kandel A, Basnet K, Karki S, Kamal M, Khan S, Kausar H, Parajuli SB, Dahiya DS.   +12 more
europepmc   +1 more source

Combination GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy on arrhythmia outcomes in non-diabetic obese patients: A real-world time-dependent analysis. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Blankson GA, Acheampong IA, Carboo AK, Kumi DD, Amoah J, Nawal A, Nii-Ashie Djanie S, Prempeh I, Seidu A, Buckner RKE.   +9 more
europepmc   +1 more source

Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis. [PDF]

Front Med (Lausanne)
Xie Y, Zhang X, Chen B.
europepmc   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP-1 Receptor Agonist. [PDF]

Mov Disord Clin Pract
Kelly H, Davis T.
europepmc   +1 more source